Evidence map›Paper›PMID 38673919›Full record

ArticleInternational journal of molecular sciences2024

D-Loop Mutations as Prognostic Markers in Glioblastoma-A Pilot Study.

Bartosz Szmyd, Patrycja Stanisławska, Małgorzata Podstawka, Karol Zaczkowski, Patryk M Izbiński, Dominika Kulczycka-Wojdala, Robert Stawski, Karol Wiśniewski, Karolina Janczar, Marcin Braun and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Bartosz SzmydDepartment of Neurosurgery and Neuro-Oncology, Barlicki University Hospital, Medical University of Lodz, 90-153 Lodz, Poland.ORCID 0000-0002-4051-0887
Patrycja StanisławskaDepartment of Neurosurgery and Neuro-Oncology, Barlicki University Hospital, Medical University of Lodz, 90-153 Lodz, Poland.
Małgorzata PodstawkaDepartment of Neurosurgery and Neuro-Oncology, Barlicki University Hospital, Medical University of Lodz, 90-153 Lodz, Poland.
Karol ZaczkowskiDepartment of Neurosurgery and Neuro-Oncology, Barlicki University Hospital, Medical University of Lodz, 90-153 Lodz, Poland.
Patryk M IzbińskiDepartment of Neurosurgery and Neuro-Oncology, Barlicki University Hospital, Medical University of Lodz, 90-153 Lodz, Poland.
Dominika Kulczycka-WojdalaCentral Scientific Laboratory, Medical University of Lodz, 93-513 Lodz, Poland.
Robert StawskiDepartment of Clinical Physiology, Medical University of Lodz, 92-215 Lodz, Poland.ORCID 0000-0003-4164-4817
Karol WiśniewskiDepartment of Neurosurgery and Neuro-Oncology, Barlicki University Hospital, Medical University of Lodz, 90-153 Lodz, Poland.ORCID 0000-0001-8736-0305
Karolina JanczarDepartment of Pathology, Medical University of Lodz, 92-213 Lodz, Poland.
Marcin BraunDepartment of Pathology, Medical University of Lodz, 92-213 Lodz, Poland.ORCID 0000-0003-3804-7042
Piotr BiałasiewiczDepartment of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, 92-215 Lodz, Poland.
Dariusz J JaskólskiDepartment of Neurosurgery and Neuro-Oncology, Barlicki University Hospital, Medical University of Lodz, 90-153 Lodz, Poland.ORCID 0000-0002-9971-9677
Ernest J BobeffDepartment of Neurosurgery and Neuro-Oncology, Barlicki University Hospital, Medical University of Lodz, 90-153 Lodz, Poland.ORCID 0000-0003-1891-3791
Medical University of Lodz · PL

Funding

National Science Center 2022/06/X/NZ2/01441
6 · The paper itself

Abstract

Glioblastoma, a highly aggressive brain tumor, poses significant treatment challenges. A deeper investigation into its molecular complexity is essential for the identification of novel prognostic biomarkers and therapeutic strategies, potentially improving patient outcomes in terms of survival and quality of life. While nuclear DNA mutations have been extensively studied, the role of mitochondrial DNA (mtDNA) mutations, specifically in the D-loop region, remains poorly understood. This prospective case-control study aimed to assess the prognostic significance of the mtDNA D-loop m.16126T>C variant in glioblastoma patients. Immunohistochemistry and droplet digital PCR (ddPCR) were employed for mutation analysis, complemented by statistical analyses and a literature review. The study cohort comprised 22 glioblastoma patients (mean age 59.36 ± 14.17, 12 (54.55%) females), and 25 controls (59.48 ± 13.22, 12 (80%) females). The D-loop m.16126T>C variant was observed in four (18%) of the glioblastoma samples and was associated with shorter median survival (9.5 vs. 18 months;

Indexed as

Biomarkers, TumorBrain NeoplasmsDNA, MitochondrialGlioblastomaMutationAdultAgedCase-Control StudiesFemaleHumansMaleMiddle AgedPilot ProjectsPrognosisProspective StudiesBiomarkers, TumorDNA, MitochondrialbiomarkersD-loop m.16126T>CD-loop variantsglioblastomamitochondrial DNAprognosis

Identifiers

PMID38673919
PMCPMC11050196
OpenAlexW4394808016

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.